Financials
Financial year 2025
ES PHARMA from Mol, company number BE1009079320, closed financial year 2025 with a result of € 32,777 after tax. For that financial year ES PHARMA recorded a gross margin of € 49,163 and equity of € 46,820. Compared with financial year 2024, the result moved from € 11,043 to € 32,777. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 3, 2026.
€ 46,820
▲ 233% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 32,777
▲ 197% vs 2024
Profit after tax over the fiscal year.
€ 58,575
▲ 258% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 43,820.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 22,609
▼ 23% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 22,226
▼ 20% vs 2024
€ 5,885 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 1,205
▲ 4% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 6,471
▼ 5% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € 18,464 | € 49,163 | ▲ 166% |
| Profit after taxes | € 11,043 | € 32,777 | ▲ 197% |
| Equity | € 14,043 | € 46,820 | ▲ 233% |
| Total debts | € 41,411 | € 37,870 | ▼ 9% |
| Cash | € 16,344 | € 58,575 | ▲ 258% |
| Retained profit | € 11,043 | € 43,820 | ▲ 297% |
| Bank debt | € 27,879 | € 22,226 | ▼ 20% |
| Balance sheet total | € 55,454 | € 84,690 | ▲ 53% |
Key figures of ES PHARMA, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ES PHARMA?
What happened at ES PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 32,777 (▲ 197% vs 2024). Source: NBB ↗
- New establishment in Mol. KBO
- Emma Smet became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 11,043 profit in 2024 to € 32,777 profit in 2025.
Paid € 11,384 in corporate taxes since 2024.
Best year ever: 2025, with € 32,777 profit.
Management
Behind ES PHARMA is Emma Smet.
Directors
According to the 2025 annual accounts
Emma Smet
Director
since 2024
Establishments
Establishment units
Physical locations of this company
Zandputlaan 38
2400 Mol
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1009.079.320
- VAT number
- BE 1009.079.320
- Registered office
- Zandputlaan 38, 2400 Mol
- Names & denominations
- ES PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 3 May 2024
- Peppol
- Active · Active since 2 Jul 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Vervaardiging van geneesmiddelen
Detailhandel in cosmetica en toiletartikelen
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Overige zakelijke dienstverlening, neg
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels